Corpus Intelligence IC Memo — HOSPITALS OF PROV TRANSMOUNTAIN CAMP 2026-04-26 08:50 UTC
IC Memo — HOSPITALS OF PROV TRANSMOUNTAIN CAMP
Investment Committee Memorandum | TX | 108 beds | Grade C | EBITDA uplift $10.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITALS OF PROV TRANSMOUNTAIN CAMP

CCN 670120 | EL PASO, TX | 108 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITALS OF PROV TRANSMOUNTAIN CAMP is a 108-bed suburban community hospital in EL PASO, TX with $143.7M in net patient revenue and a 5.9% operating margin. The hospital serves a payer mix of 20.2% Medicare, 4.9% Medicaid, and 74.8% commercial.

Thesis: Turnaround. Our ML models identify $10.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.9% to 13.3% (+736bps).

Net Revenue HCRIS$143.7M
Current EBITDA COMPUTED$8.5M
Operating Margin COMPUTED5.9%
Occupancy HCRIS65.0%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS10.7%
Distress Probability ML42.3%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
191
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 5.9% places it above the state median. Among 191 size-comparable peers (54-216 beds), the median margin is 2.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (54-216), prioritizing same-state peers. 191 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITALS OF PROV TRANSMOUNTAI (Target)TX108$143.7M5.9%
DRISCOLL CHILDRENS HOSPITALTX215$694.3M29.4%
ROUND ROCK HOSPITALTX165$681.4M8.7%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%
COVENANT CHILDRENS HOSPITALTX181$410.3M15.5%
COLLEGE STATION HOSPITALTX135$397.7M-0.9%
MEMORIAL HERMANN KATYTX196$381.4M13.3%
CHILDRENS HOSPITAL OF SAN ANTOTX174$376.5M-2.8%
MEDICAL CITY FORT WORTHTX209$375.9M22.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.0M+210bp18mo
Cost to Collect4.5%2.5%$2.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$92K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.0M
Cost to Collect
$2.9M
Denial Rate Reduction
$2.8M
A/R Days Reduction
$1.7M
Clean Claim Rate
$92K
Total EBITDA Uplift$10.6M
Current EBITDA$8.5M
+ RCM Uplift+$10.6M
Pro Forma EBITDA$19.1M
Current Margin5.9%
Pro Forma Margin13.3%
WC Released (1x)$5.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$13.1M$162.1M12.35x65.3%
Base (11x exit)10.0x11.0x$13.1M$182.6M13.91x69.3%
Bull Case9.0x11.0x$11.8M$221.8M18.77x79.8%
Bull (12x exit)9.0x12.0x$11.8M$245.4M20.77x83.4%
Bear Case11.0x10.0x$14.4M$104.9M7.27x48.7%
Bear (11x exit)11.0x11.0x$14.4M$120.1M8.32x52.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 191 hospitals with 54-216 beds
  • Same-state prioritization (n=192)
  • Comp margins: P25=-10.3% / P50=2.2% / P75=11.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.